Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial

BACKGROUND: Glioblastoma (GBM) has a 5-year survival rate of 3%-5%. GBM treatment includes maximal resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ). Cytochrome C oxidase (CcO) is a mitochondrial enzyme involved in the mechanism of resistance to TMZ. In a prior retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Griguer, Corinne E, Oliva, Claudia R, Coffey, Christopher S, Cudkowicz, Merit E, Conwit, Robin A, Gudjonsdottir, Anna L, Ecklund, Dixie J, Fedler, Janel K, Neill-Hudson, Tina M, Nabors, Louis B, Benge, Melanie, Hackney, James R, Chase, Marianne, Leonard, Timothy P, Patel, Toral, Colman, Howard, de la Fuente, Macarena, Chaudhary, Rekha, Marder, Karen, Kreisl, Teri, Mohile, Nimish, Chheda, Milan G, McNeill, Katharine, Kumthekar, Priya, Dogan, Aclan, Drappatz, Jan, Puduvalli, Vinay, Kowalska, Agnes, Graber, Jerome, Gerstner, Elizabeth, Clark, Stephen, Salacz, Michael, Markert, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788017/
https://www.ncbi.nlm.nih.gov/pubmed/35088051
http://dx.doi.org/10.1093/noajnl/vdab186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788017/
https://www.ncbi.nlm.nih.gov/pubmed/35088051
http://dx.doi.org/10.1093/noajnl/vdab186

Ejemplares similares